JOHNSON JAMES A 4

What Happened
James A. Johnson, a director of LeonaBio, was granted a derivative award on April 9, 2026 covering 28,000 shares. The Form 4 reports an acquisition amount of 28,000 shares at $0.00 (total reported value $0) — recorded as a derivative instrument (an option) rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-04-09; Form 4 filed 2026-04-13.
• Reported price: $0.00 per share; reported total value $0 (derivative award).
• Vesting: The option vests monthly over 24 months (monthly anniversaries), contingent on continued service under the issuer’s 2026 Equity Incentive Plan (see footnote).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Filing timeliness: Form 4 filed 4 days after the transaction (no late-filing flag provided in the excerpt).

Context
This was an equity compensation award (an option) for a director, not an open-market purchase or sale. Such grants are common as part of director compensation and reflect remuneration rather than an immediate personal buy or sell decision. The award vests over two years, so the shares/options become exercisable gradually if the director remains a service provider. This filing does not indicate any immediate sale of shares.